948 related articles for article (PubMed ID: 20109994)
1. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.
Montanya E; Sesti G
Clin Ther; 2009 Nov; 31(11):2472-88. PubMed ID: 20109994
[TBL] [Abstract][Full Text] [Related]
2. Next-generation GLP-1 therapy: an introduction to liraglutide.
Repas T
Postgrad Med; 2011 Sep; 123(5):239-47. PubMed ID: 21904107
[TBL] [Abstract][Full Text] [Related]
3. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?
Halimi S
Diabetes Metab; 2008 Feb; 34 Suppl 2():S91-5. PubMed ID: 18640591
[TBL] [Abstract][Full Text] [Related]
4. An overview of the pharmacokinetics, efficacy and safety of liraglutide.
Bode B
Diabetes Res Clin Pract; 2012 Jul; 97(1):27-42. PubMed ID: 22245694
[TBL] [Abstract][Full Text] [Related]
5. Liraglutide: once-daily GLP-1 agonist for the treatment of type 2 diabetes.
Ryan GJ; Hardy Y
J Clin Pharm Ther; 2011 Jun; 36(3):260-74. PubMed ID: 21545609
[TBL] [Abstract][Full Text] [Related]
6. Liraglutide - overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes.
Davies MJ; Kela R; Khunti K
Diabetes Obes Metab; 2011 Mar; 13(3):207-20. PubMed ID: 21205109
[TBL] [Abstract][Full Text] [Related]
7. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
Tzefos M; Harris K; Brackett A
Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
[TBL] [Abstract][Full Text] [Related]
8. Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents.
Blonde L; Montanya E
Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():20-32. PubMed ID: 22405266
[TBL] [Abstract][Full Text] [Related]
9. The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients.
Flint A; Kapitza C; Hindsberger C; Zdravkovic M
Adv Ther; 2011 Mar; 28(3):213-26. PubMed ID: 21340616
[TBL] [Abstract][Full Text] [Related]
10. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
Wang B; Zhong J; Lin H; Zhao Z; Yan Z; He H; Ni Y; Liu D; Zhu Z
Diabetes Obes Metab; 2013 Aug; 15(8):737-49. PubMed ID: 23433305
[TBL] [Abstract][Full Text] [Related]
11. Willingness to pay for diabetes drug therapy in type 2 diabetes patients: based on LEAD clinical programme results.
Jendle J; Torffvit O; Ridderstråle M; Ericsson Å; Nilsen B; Bøgelund M
J Med Econ; 2012; 15 Suppl 2():1-5. PubMed ID: 22853443
[TBL] [Abstract][Full Text] [Related]
12. Liraglutide in type 2 diabetes: from pharmacological development to clinical practice.
Rossi MC; Nicolucci A
Acta Biomed; 2009 Aug; 80(2):93-101. PubMed ID: 19848045
[TBL] [Abstract][Full Text] [Related]
13. Liraglutide: from clinical trials to clinical practice.
Gough SC
Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():33-40. PubMed ID: 22405267
[TBL] [Abstract][Full Text] [Related]
14. Current treatments and strategies for type 2 diabetes: can we do better with GLP-1 receptor agonists?
Peterson G
Ann Med; 2012 Jun; 44(4):338-49. PubMed ID: 22530845
[TBL] [Abstract][Full Text] [Related]
15. Clinical studies of liraglutide, a novel, once-daily human glucagon-like peptide-1 analog for improved management of type 2 diabetes mellitus.
Drab SR
Pharmacotherapy; 2009 Dec; 29(12 Pt 2):43S-54S. PubMed ID: 19947816
[TBL] [Abstract][Full Text] [Related]
16. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
Boland CL; Degeeter M; Nuzum DS; Tzefos M
Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
[TBL] [Abstract][Full Text] [Related]
17. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).
Buse JB; Rosenstock J; Sesti G; Schmidt WE; Montanya E; Brett JH; Zychma M; Blonde L;
Lancet; 2009 Jul; 374(9683):39-47. PubMed ID: 19515413
[TBL] [Abstract][Full Text] [Related]
18. Liraglutide: effects beyond glycaemic control in diabetes treatment.
McGill JB
Int J Clin Pract Suppl; 2010 Oct; (167):28-34. PubMed ID: 20887302
[TBL] [Abstract][Full Text] [Related]
19. Incretins: a new treatment option for type 2 diabetes?
Geelhoed-Duijvestijn PH
Neth J Med; 2007 Feb; 65(2):60-4. PubMed ID: 17379930
[TBL] [Abstract][Full Text] [Related]
20. Liraglutide: a review of the first once-daily GLP-1 receptor agonist.
Bode B
Am J Manag Care; 2011 Mar; 17(2 Suppl):S59-70. PubMed ID: 21517658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
